| 1648 |
495: Repressed expression of steroidogenic enzymes |
413: Reduction, Testosterone synthesis in Leydig cells |
Aug 11, 2017 |
Aug 11, 2017 |
1 AOP
|
| 3615 |
495: Repressed expression of steroidogenic enzymes |
1690: Decrease, circulating testosterone levels |
Sep 3, 2025 |
Sep 3, 2025 |
1 AOP
|
| 3623 |
495: Repressed expression of steroidogenic enzymes |
3: Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
Sep 3, 2025 |
Sep 3, 2025 |
None
|
| 2436 |
1902: Repression of Gbx2 expression |
1903: foxi1 expression, increased |
Jul 14, 2021 |
Aug 13, 2021 |
1 AOP
|
| 433 |
445: Respiratory distress/arrest |
351: Increased Mortality |
Nov 29, 2016 |
Dec 20, 2019 |
1 AOP
|
| 592 |
445: Respiratory distress/arrest |
590: N/A, hypoxia |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 378 |
397: Response, Keratinocytes |
398: Activation, Dendritic Cells |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 380 |
397: Response, Keratinocytes |
272: Activation/Proliferation, T-cells |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1915 |
1637: Retinaldehyde dehydrogenase |
1641: retinoic acid |
May 22, 2019 |
May 22, 2019 |
1 AOP
|
| 3036 |
2186: Activation, RyR |
1350: Increased, glutamate |
Sep 8, 2023 |
Sep 8, 2023 |
1 AOP
|
| 2052 |
1738: SARS-CoV-2 cell entry |
1496: Increased proinflammatory mediators |
Mar 1, 2020 |
Mar 1, 2020 |
None
|
| 2302 |
1738: SARS-CoV-2 cell entry |
1848: TLR Activation/Dysregulation |
Mar 29, 2021 |
Mar 29, 2021 |
None
|
| 2310 |
1738: SARS-CoV-2 cell entry |
1847: SARS-CoV-2 production |
Mar 30, 2021 |
Feb 7, 2023 |
2 AOPs
|
| 2314 |
1738: SARS-CoV-2 cell entry |
1858: Increased viral transcription and replication |
Apr 9, 2021 |
Apr 9, 2021 |
None
|
| 2361 |
1738: SARS-CoV-2 cell entry |
1870: Sustentacular cells, decrease |
Apr 26, 2021 |
Apr 26, 2021 |
None
|
| 2496 |
1738: SARS-CoV-2 cell entry |
1901: IFN-I response, antagonized |
Oct 24, 2021 |
Dec 12, 2023 |
5 AOPs
|
| 2510 |
1738: SARS-CoV-2 cell entry |
1913: Endothelial cell dysfunction |
Oct 28, 2021 |
Oct 28, 2021 |
None
|
| 2661 |
2006: Secondary genotoxicity |
1669: Increased, DNA damage and mutation |
May 25, 2022 |
May 25, 2022 |
1 AOP
|
| 1588 |
1437: Sensing of the stressor |
1438: Increased transcription of genes encoding acute phase proteins |
Jun 29, 2017 |
Jun 29, 2017 |
None
|
| 2657 |
1583: Sensory axonal peripheral neuropathy |
351: Increased Mortality |
May 16, 2022 |
May 16, 2022 |
1 AOP
|
| 3066 |
1583: Sensory axonal peripheral neuropathy |
618: Decreased, Neuronal network function in adult brain |
Oct 17, 2023 |
Oct 17, 2023 |
1 AOP
|
| 3067 |
1583: Sensory axonal peripheral neuropathy |
388: Overactivation, NMDARs |
Oct 17, 2023 |
Oct 17, 2023 |
None
|
| 1571 |
1431: Serotonin 1A Receptor Agonism |
1426: Release of G Proteins |
Jun 23, 2017 |
Jun 23, 2017 |
2 AOPs
|
| 1499 |
1390: Sexual behavior, decreased |
1141: Decreased, Reproductive Success |
May 8, 2017 |
May 8, 2017 |
1 AOP
|
| 3562 |
2329: SIX1 gene expression, increased |
2330: SIX1 protein expression, increased |
Aug 5, 2025 |
Sep 18, 2025 |
1 AOP
|